NewsXbrane Biopharma reports positive in-vivo efficacy data on Spherotide

Xbrane Biopharma has, in preparation for upcoming clinical trials, done a comparative study in minipigs on the 1 month formulation of Spherotide. The study involved two groups of ten minipigs in total, receiving one injection of Spherotide and the originator product, respectively. The primary objective of the study was to compare the testosterone suppression in the subjects 1 month after injection which, after scientific advice with regulatory authorities, will be the primary endpoint in the pivotal phase III clinical study for Spherotide. The secondary objective of the study was to compare the pharmacokinetic profiles, even though this will not be the primary endpoint of the upcoming clinical trial.

Spherotide demonstrated no significant difference vs. the originator product on the clinically relevant endpoint, testosterone suppression 1 month after injection. Further, Spherotide demonstrated no significant difference in the safety profile vs. the originator product. The pharmacokinetic profile of Spherotide demonstrated a higher concentration maximum (Cmax) and higher total drug exposure (AUCinf) compared to the originator product. The study was performed by CiToxLAB in Denmark under GLP (Good Laboratory Practice).

“The primary endpoint in the upcoming clinical study will be related to testosterone suppression during the end of the treatment period for one injection. Seeing no significant difference between Spherotide and the originator product on that endpoint in this in-vivo trial in a larger animal gives us further confidence in Spherotide ahead of the clinical trials”, says Martin Åmark, Xbranes CEO.

Spherotide is a generic long acting formulation with the active substance triptorelin (originator product Decapeptyl®/Pamorelin®/Trelstar®) and is used primarily in the treatment of prostate cancer, endometriosis and uterine fibroids. The drug is based on encapsulation of the active ingredient in biodegradable microspheres that degrade in the body after injection and create a long acting effect.

For further information, please contact:
Martin Åmark, Chief Executive Officer
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com